ALAUNOS THERAPEUTICS INC (TCRT)       0.6934  -0.01 (-0.94%)

0.6934  -0.01 (-0.94%)

US98973P1012 - Common Stock - After market: 0.74 +0.05 (+6.72%)

ALAUNOS THERAPEUTICS INC0.6934

NASDAQ:TCRT (2/3/2023, 7:10:35 PM)-0.01 (-0.94%)

After market: 0.74 +0.05 (+6.72%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 11-14 2022-11-14/bmo Earnings (Next) 03-28 2023-03-28/amc
Ins Owners 1.38% Inst Owners N/A
Market Cap 166.70M Shares 240.41M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 78.33
IPO 08-20 2004-08-20

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

TCRT Daily chart

Company Profile

Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. The company is headquartered in Houston, Texas and currently employs 41 full-time employees. The company went IPO on 2004-08-20. The firm is engaged in developing adoptive TCR engineered T-cell therapies (TCR-T), designed to treat multiple solid tumor types in large cancer patient populations. The firm is leveraging its cancer mutation hotspot TCR library and its non-viral Sleeping Beauty genetic engineering technology to design and manufacture patient-specific cell therapies that target neoantigens arising from common tumor-related mutations in key oncogenic genes, including KRAS, TP53 and EGFR. Its TCR library consists of ten TCRs targeting six solid tumor indications, including non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers. Using its human neoantigen T cell Receptor (hunTR) discovery engine, it analyzes thousands of single T cells simultaneously using bioinformatics and next generation sequencing. Its pipeline includes Library TCR-T cell therapy and mbIL-15 TCR-T cell therapy.

Company Info

ALAUNOS THERAPEUTICS INC

8030 El Rio Street, Parris Building 34, Navy Yard Plaza

Houston TEXAS

P: 13463554099.0

Employees: 41

Website: https://alaunos.com/

TCRT News

News Imagea month ago - Alaunos Therapeutics, Inc.Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023

Announcing addition of two new TCRs to the library, estimated to double the addressable market; plans to further expand TCR library using hunTR® TCR...

News Image2 months ago - Alaunos Therapeutics, Inc.Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock

HOUSTON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell...

News Image2 months ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning! It's time for another dive into the biggest pre-market stock movers with the shares rising and falling on Tuesday!

News Image2 months ago - Seeking AlphaAlaunos Therapeutics proposes stock offering to fund research pipeline (NASDAQ:TCRT)

Alaunos Therapeutics (TCRT) has started off underwritten stock offering, the clinical-stage oncology company told in after-hours on Monday.Price, size and other terms not...

News Image2 months ago - Alaunos Therapeutics, Inc.Alaunos Therapeutics Announces Proposed Public Offering of Common Stock

HOUSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell...

News Image3 months ago - Alaunos Therapeutics, Inc.Alaunos Therapeutics Reports Third Quarter 2022 Financial Results

Presented early data highlighting first successful objective clinical response using non-viral Sleeping Beauty TCR-T cell therapy in solid tumors at the...

TCRT Twits

Here you can normally see the latest stock twits on TCRT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example